Abstract: The present disclosure is directed toward uses of compound 1 (or its stereoisomers) and compositions and/or dosage forms containing compound 1: or a pharmaceutically acceptable salt thereof. Some uses of Compound 1 and/or its stereoisomers include treating a variety of diseases and disorders, including pain, depression, and schizophrenia. In some embodiments, Compound 1 and/or its stereoisomers may be useful in the treatment of a substance use disorder while inducing fewer withdrawal symptoms than a standard-of-care opioid addiction treatment.

Abstract: The present disclosure is directed toward uses of compound 1 (or its stereoisomers) and compositions and/or dosage forms containing compound 1: or a pharmaceutically acceptable salt thereof. Some uses of Compound 1 and/or its stereoisomers include treating a variety of diseases and disorders, including pain, depression, and schizophrenia. In some embodiments, Compound 1 and/or its stereoisomers may be useful in the treatment of a substance use disorder while inducing fewer withdrawal symptoms than a standard-of-care opioid addiction treatment.

Abstract: The present disclosure is directed toward uses of compound 1 (or its stereoisomers) and compositions and/or dosage forms containing compound 1, wherein compound 1 is N-[2,5-dimethyl-1-(2-phenylethyl)piperidin-4-yl]-N-phenylpropanamide.

Abstract: The disclosure provides a method of treating a substance use disorder in a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising R(?)-ketamine or a pharmaceutically acceptable salt thereof, wherein the composition is substantially free of S(+)-ketamine or a pharmaceutically acceptable salt thereof.

Abstract: The disclosure provides a method of treating a substance use disorder in a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising R(?)-ketamine or a pharmaceutically acceptable salt thereof, wherein the composition is substantially free of S(+)-ketamine or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure is directed toward uses of compound 1 (or its stereoisomers) and compositions and/or dosage forms containing compound 1: or a pharmaceutically acceptable salt thereof. Some uses of Compound 1 and/or its stereoisomers include treating a variety of diseases and disorders, including pain, depression, and schizophrenia. In some embodiments, Compound 1 and/or its stereoisomers may be useful in the treatment of a substance use disorder while inducing fewer withdrawal symptoms than a standard-of-care opioid addiction treatment.

Abstract: The disclosure provides a method of treating a substance use disorder in a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising R(?)-ketamine or a pharmaceutically acceptable salt thereof, wherein the composition is substantially free of S(+)-ketamine or a pharmaceutically acceptable salt thereof.